DEALS: GSK, ChemoCentryx ink $1.5B pact


GSK, ChemoCentryx ink $1.5B pact


DEALS

WHO

WITH

WHAT

SCOOP

GlaxoSmithKline

ChemoCentryx

$1.5B collaboration pact

The deal revolves around developing new therapies from chemokine and chemoattractant receptors for inflammatory diseases.

Mylan Laboratories

Matrix Laboratories

$735 million acquisition

In a move to expand its reach around the globe, Mylan Laboratories has acquired a majority interest in India's Matrix Laboratories.

Infinity Pharmaceuticals

MedImmune

$500M development deal

Infinity Pharmaceuticals and MedImmune will advance new therapies for blood-related cancers and solid tumors.

Dishman Pharmaceuticals and Chemicals

Carbogen Amcis

$75M purchase

Carbogen Amcis controls three production facilities. Dishman says it expects to be able to improve margins at the contract manufacturing operation.

Dyax

Paul Capital Partners

$30M payment

Dyax receives the payment from Paul Capital Partners in exchange for a portion of the revenue generated by its Phage Display Licensing and Funded Research Program.

Isolagen

Agera Laboratories

$2.67M deal

Agera Laboratories makes clinically developed skincare products.

Orthodontix

Protalix

Merger

Once the merger is complete a small group of investors will invest $15 million in Protalix in exchange for 14 percent of the company.